Related Experiment Video
Updated: Jun 20, 2026

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
Targeted RNA interference for hepatic fibrosis
1Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 20003, China.
Abstract:
Hepatic fibrosis is a common consequence in patients with chronic liver damage. To date, no agent has been approved for the treatment of hepatic fibrosis. RNA interference (RNAi) is known to be a powerful tool for post-transcriptional gene silencing and has opened new avenues in gene therapy. The problems of lack of cell specificity in vivo and subsequently the occurrence of side effects has hampered the development of hepatic fibrosis treatment. To overcome these shortcomings, several targeted strategies have been developed, such as hydrodynamics-based approaches, local administration, cell-type-selective ligands and cell-type-specific promoters or enhancers, etc. Here, we provide an overview of targeted strategies for the treatment of hepatic fibrosis, and particularly, targeted RNAi for hepatic fibrosis.
Insights
Targeted RNA interference (RNAi) offers a promising approach for treating hepatic fibrosis, a condition with no current approved therapies. Strategies focus on improving cell specificity to minimize side effects and enhance treatment efficacy.
Area of Science:
- Biomedical research
- Gene therapy
- Hepatology
Background:
- Hepatic fibrosis results from chronic liver damage and lacks approved treatments.
- RNA interference (RNAi) is a gene silencing technique with therapeutic potential.
- Current challenges include lack of in vivo cell specificity and associated side effects.
Purpose of the Study:
- To review targeted strategies for hepatic fibrosis treatment.
- To highlight the role of targeted RNA interference (RNAi) in this context.
Main Methods:
- Overview of existing targeted strategies.
- Focus on cell-type-selective ligands and promoters/enhancers.
- Discussion of hydrodynamics-based and local administration approaches.
Main Results:
- Targeted strategies aim to improve the safety and efficacy of RNAi therapy.
- Overcoming cell specificity issues is crucial for clinical translation.
- Various methods are being explored to direct RNAi specifically to liver cells.
Conclusions:
- Targeted RNAi presents a viable therapeutic avenue for hepatic fibrosis.
- Further development of targeted delivery systems is essential.
- Addressing specificity and side effects will enable clinical application.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibitors of Viral Protein Synthesis
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
